Table 2 Treatment administered to the subset of patients enrolled in the ChemoFx (Precision Therapeutics, Inc., Pittsburgh, PA) Physician Reported Outcomes Study between assays
From: In vitro chemoresponse in metachronous pairs of gyneclologic cancers
N = 36 | |
|---|---|
Bevacizumab/Carboplatin/Paclitaxel | 2 (6%) |
Carboplatin/Cisplatin/Paclitaxel | 7 (19%) |
Carboplatin/Gemcitabine/Paclitaxel | 1 (3%) |
Carboplatin/Docetaxel | 2 (6%) |
Carboplatin/Paclitaxel | 22 (61%) |
Cisplatin/Docetaxel/Paclitaxel | 1 (3%) |
Cisplatin/Paclitaxel | 1 (3%) |